Open AccessVenetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Author(s) -
Naval Daver,
Alexander E. Perl,
Joseph Maly,
Mark J. Levis,
Ellen K. Ritchie,
Mark R. Litzow,
James McCloskey,
Catherine C. Smith,
Gary J. Schiller,
Terrence Bradley,
Ramón V. Tiu,
Kiran Naqvi,
Monique Dail,
Deanna J. Brackman,
Satya R. Siddani,
Jing Wang,
Brenda Chyla,
Paul Lee,
Jessica K. Altman
Publication year - 2022
Publication title -
journal of clinical oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.22.00602
Subject(s) - venetoclax , medicine , refractory (planetary science) , myeloid leukemia , gastroenterology , adverse effect , myeloid , leukemia , surgery , chronic lymphocytic leukemia , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom